ATANTARES won CNY 100 Mn Pre-A round financing, molecular chip drives high-throughput DNA
Summary
Shanghai Xinsu Medical Technology Co., Ltd. (hereinafter referred to as "ATANTARESChinese") has completed the 100 million yuan Pre-A round and Pre-A + round of financing, on July 31, 2023.Organized by Asia Green FundChinese, Fosun Groups FOSUN HEALTH CAPITALChinese, Alibaba HealthChineseand FREEFUNDChinese, QIMING VENTUR E PAR TNERSChineseand other old shareowners participated in the investment. Committed to using semiconductor technology to empower biomedicine, using the inherent miniaturization and high integration characteristics of silicon chips and microfluidic technology to provide ultra-high throughput and ultra-high sensitivity to meet the needs of rapid development in fields such as medical health, synthetic biology and DNA storage.ATANTARES took the lead in proposing and independently developed the first molecular chip in China, which opened the innovation trend of semiconductization of biotechnology driven by silicon-based chips in China. The first monetization application is DNA synthesis based on molecular chips, which is a typical interdisciplinary entrepreneurship. It is a key force leading a new round of scientific and technological revolution and industrial transformation.In the future, ATANTARES will go overseas at a relatively low price to meet the needs of the US and other biotechnology markets ; Zhao Xinxin, founder of ATANTARES, believes that "high-throughput quantification of DBTL cycles in biotechnology research and development is a trend, and it also promotes DNA synthesis technology to high throughput." AI , as a tool for characterizing high-dimensional space , has generated a large number of sequences that require high-throughput synthesis.